10:54 AM EDT, 07/18/2024 (MT Newswires) -- Ionis Pharmaceuticals ( IONS ) said Thursday it completed enrollment in a clinical trial of zilganersen, an investigational ribonucleic acid-targeted medicine to treat children and adults with Alexander disease, a neurological disorder.

Topline data are expected in H2 2025.

The study "is the first trial to evaluate an investigational medicine designed to address the underlying cause of Alexander disease," said Eugene Schneider, chief clinical development officer of Ionis.

The trial also includes an open-label study in participants under the age of two, which will continue to enroll into 2025, the company said.

Ionis shares fell 1.7% in recent trading Thursday.

Price: 47.14, Change: -0.82, Percent Change: -1.71